MRKR News and Press, Marker Therapeutics Inc. From 05/08/23

HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the app...

2023-05-01 12:10:17 ET If you’re looking for some of the most active penny stocks today, it doesn’t hurt to pay attention to trends. I’m not talking about what’s going on in tech or the latest energy stocks to watch. I’m referring to more micro trends. Thi...

2023-05-01 09:09:13 ET Marker Therapeutics ( NASDAQ: MRKR ) signed an agreement with CellReady, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, Marker's co-founder and board member. Under the non-dilutive agreement, CellReady wil...

Structured To Extend Marker’s Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage company speciali...

2023-03-22 13:29:15 ET Gainers: GameStop ( GME ) +41% . Telesis Bio ( TBIO ) +31% . EZGO Technologies ( EZGO ) +33% . CorEnergy Infrastructure ( CORR ) +28% . 89bio ( ETNB ) +25% . JanOne ( JAN ) +27% . InMed Phar...

2023-03-22 08:45:31 ET Marker Therapeutics press release ( NASDAQ: MRKR ): FY GAAP EPS of -$3.58 beats by $0.02 . Revenue of $9.01M (+626.6% Y/Y) beats by $0.01M . At December 31, 2022, Marker had cash and cash equivalents of $11.8 million. The Company believ...

2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia (AML) Investigational New Drug (IND) application cleared by FDA for multicenter Phase 1 tri...

Immuno-oncology company Marker Therapeutics ( NASDAQ: MRKR ) has entered into a common stock purchase agreement with Lincoln Park Capital Fund, under which the latter will purchase up to $25M of shares of the company's common stock over a 24-month period. Marker ( MRKR ) antic...

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today ann...

HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...